Beta Bionics, Inc.(BBNX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Beta Bionics, Inc. (BBNX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BBNX at 29.8/100 on a 32-signal composite quality model, placing it at rank #2,514 of 2,962 stocks — the bottom half of the AI-ranked universe. BBNX scores in the top quartile across revenue growth (88.0). Areas of concern include free cash flow (9.2) and balance sheet strength (9.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Beta Bionics, Inc. reports quarterly revenue of $32.0M, net income of $-23.4M, an operating margin of -79.9%. Top institutional holders of BBNX by reported 13-F value include EVENTIDE ASSET MANAGEMENT, Soleus Capital Management, L.P., MORGAN STANLEY, based on the most recent SEC filings. BBNX trades on the Nasdaq exchange and files with the SEC under CIK 1674632. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beta Bionics, Inc. directly from SEC EDGAR.